Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Cholinergic replacement therapies have yielded little or no clinical improvement in Alzheimer's disease (AD). Since the number of postsynaptic muscarinic receptors remains unchanged in the cerebral cortex, the involvement of other neurotransmitter systems may account for this limited efficacy. Alternatively, there may be a defective coupling of the muscarinic receptor with its nucleotide‐binding protein in AD, which would severely limit the ability of cholinergic agonists to activate intracortical second messengers. To address this possibility, we assessed the ability of the putative M1 muscarinic receptor to form high‐affinity agonist‐receptor complexes with guanine nucleotide regulatory proteins in postmortem frontal cortex. Agonist affinity states of the M1 muscarinic receptor were measured by carbachol/[3 H]‐pirenzepine competition. M1 muscarinic receptors exhibited both high (K H) and low (K L) affinities for the agonist carbachol. High‐affinity agonist binding to M1 receptors in postmortem frontal cortex samples from subjects with AD was reduced, demonstrated by an increase in the K H value. Low‐affinity agonist binding (K L value) was unchanged in AD and was not significantly different from the K L value for the uncoupled receptor determined in the presence of guanine nucleotides. The increase in the K H value resulted in a 70% decrease in the average K L/K H ratio for AD as compared to control samples. Choline acetyltransferase activities correlated significantly with the K L/K H ratios (r = 0.73,p < 0.001). These data suggest that the K L/K H ratio for muscarinic agonists may serve as a neurochemical marker of disease severity. The reduced ability of the M1 receptor subtype to form a high‐affinity agonist state in AD may account for the failure of cholinergic replacement therapies to improve specific features of memory and cognition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Davies, P., Katzman, R., & Terry, R. D. (1980) · Nature · doi:10.1038/288279a0 · Cited by 882
Cited by
The cholinergic system in Alzheimer's disease
Kása, P., Rakonczay, Z., & Gulya, K. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00028-2 · Cited by 409
Levey, A. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13541 · Cited by 359
Aubert, I., Araujo, D. M., Cécyre, D., Robitaille, Y., Gauthier, S., & Quirion, R. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09752.x · Cited by 320
Vogt, B. A. (1993) · Neurobiology of Cingulate Cortex and Limbic Thalamus · doi:10.1007/978-1-4899-6704-6_2 · Cited by 139
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63
“…the expression levels of the M2 mAChRs are decreased but there are no significant changes to the expression level of the M1 mAChRs when compared to normal aged brain tissue (Nordberg and Winblad, 1986; Flynn et al., 1991; Hampel et al., 2018); an important consideration for therapeutic development.”
Background
Metadata
- Authors
- Flynn, D. D., Weinstein, D. A., & Mash, D. C.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1991-03
- Volume
- 29
- Issue
- 3
- Pages
- 256-262
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2102305385
- Cited by
- 146
- References
- 4
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies. https://app.cochat.ai/papers/10.1002/ana.410290305
- The paper
- Flynn, D. D., Weinstein, D. A., & Mash, D. C. (1991). Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies. Annals of Neurology. https://doi.org/10.1002/ana.410290305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.